Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion.
In the setting of allogeneic hematopoietic stem cell transplantation, ex vivo culturing of donor T lymphocytes is a necessary step for processes such as gene modification. Often the aim is to enable control of undesired alloreactivity after in vivo administration of the cultured cells. However, it is not fully understood how T cell reactivity against donor and third-party targets is affected by the ex vivo cell culturing process. We have assessed how the activity of anti-Epstein Barr virus (EBV)-specific T lymphocytes from healthy EBV-seropositive donors is affected by in vitro cell culturing. Peripheral blood mononuclear cells (PBMCs) were expanded in X-VIVO 15 culture medium supplemented with 5% human serum. The cells were stimulated by either OKT3 (10 ng/ml) and interleukin (IL)-2 (500 U/ml) or by using anti-CD3/CD28-coated immunomagnetic beads and IL-2 (100 U/ml). Induction of polyclonal EBV-specific cytotoxic T lymphocyte cultures was attempted by stimulation of the in vitro-expanded cells at different time points during the cell expansion process, with pre-established autologous EBV-transformed lymphoblastoid cell lines (LCLs). While EBV-specific cytotoxic T lymphocytes (CTL) were generated from untreated PBMCs of 5 healthy donors, EBV-specific cytotoxicity was significantly decreased or absent in CTL cultures established from in vitro-expanded PBMCs. Our results indicate that the ex vivo cell expansion process itself significantly reduces the activity and/or the number of EBV-specific T cells. Additional stimulation with CD28 antibodies could not prevent this effect. Because T cell depleted bone marrow or stem cell grafts are known to contribute to the development of post transplant lymphoproliferative disorders, this should be taken into consideration if one considers expanding and administering PBMCs in conjunction with a T cell-depleted stem cell grafts.
Carlens
S
S
The Centre for Allogeneic Stem Cell Transplantation and Department of Microbiology, Pathology and Clinical Immunobiology, Huddinge University Hospital, Stockholm, Sweden.
Liu
D
D
Ringdén
O
O
Aschan
J
J
Christensson
B
B
Levitsky
V
V
Dilber
M S
MS
D018929:Cell Culture Techniques / Q000379:methods; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D020031:Epstein-Barr Virus Infections / Q000276:immunology; D005434:Flow Cytometry / Q000379:methods; D019650:Hematopoietic Stem Cell Mobilization; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D016853:Muromonab-CD3 / Q000494:pharmacology; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000821:virology; D013997:Time Factors
D007376:Interleukin-2; D016853:Muromonab-CD3